P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL by Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chaun Wun, Wojciech Jurczak, Stephen D. Smith

Get full text

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) by Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin

Get full text

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES by Jennifer Woyach, Ian W. Flinn, Farrukh Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer Parikh, Tycel Phillips, Razi Ghori, Ima Paydar, Mohammed Z. H. Farooqui, John C. Byrd, Deborah Stephens

Get full text

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-... by Constantine Tam, Mazyar Shadman, Jeff Sharman, Gavin Cull, Tycel Phillips, Judith Trotman, Aileen Cohen, Heather Allewelt, Rocco Crescenzo, Richard Delarue, Heather Zhang, Bilal Tariq, Sri Sahasranaman, Ying C Ou, Ian W Flinn

Get full text

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas by Thomas F Gajewski, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson

Get full text